Récher, Christian, 19..-....
![Sudoc [ABES], France](/viaf/images/flags/SUDOC.png "Sudoc [ABES], France")
Christian Récher researcher (ORCID 0000-0002-3332-4525)
Recher, Christian
VIAF ID: 2222161211433940070008 ( Personal )
Permalink: http://viaf.org/viaf/2222161211433940070008
Preferred Forms
4xx's: Alternate Name Forms (1)
Works
| Title | Sources |
|---|---|
| Activation anormale de la tyrosine kinase Lyn et de la voie PI3K/Akt dans les leucémies aiguës myéloïdes (LAM) et ciblage pharmacologique |
|
| Adrenomedullin-CALCRL axis controls relapse-initiating drug tolerant acute myeloid leukemia cells |
|
| All trans retinoic acid in acute myeloid leukemias carrying isocitrate dehydrogensae mutation. |
|
| Apport de la cytométrie en flux à l'étude des leucémies aigües myéloïdes |
|
| Autophagy regulates fatty acid availability for oxidative phosphorylation through mitochondria-endoplasmic reticulum contact sites |
|
| Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study |
|
| Caractéristiques et devenir des patients atteints de leucémies aigües myéloïdes admis en réanimation à la phase inaugurale au CHU de Toulouse entre 2000 et 2013 |
|
| Characteristics and outcomes of patients with acute myeloid leukemia admitted to intensive care unit during induction treatment at the university hspital of Toulouse between 2000 and 2013. |
|
| Contribution of flow cytometry in the study of acute myeloid leukemia. |
|
| Dendrogenin A Enhances Anti-Leukemic Effect of Anthracycline in Acute Myeloid Leukemia |
|
| Hemophagocytic lymphohistiocytosis in acute myeloid leukemia treated by intensive chemotherapy : description, etiologies, treatment and pronostic impact. |
|
| Large granular lymphocytosis during quizartinib therapy |
|
| Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study |
|
| The manipulation of energetic metabolism in human acute myeloid leukemia : mitochondria, apoptosis and the mechanism of action of metformin. |
|
| Mécanisme de chimiorésistance dans les leucémies aiguës myéloïdes |
|
| Microenvironment favors FLT3-ITD AML resistance to FLT3-TKI through hypoxia- and STAT5- dependent upregulation of AXL. |
|
| Microenvironnement médullaire et résistance des LAM FLT3-ITD aux inhibiteurs de tyrosine kinase : Rôle pivot du récepteur TAM AXL |
|
| Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial. |
|
| mutation is not associated with prolonged complete remission in acute myeloid leukemia patients treated with hypomethylating agents |
|
| Oncogenic KIT mutations induce STAT3-dependent autophagy to support cell proliferation in acute myeloid leukemia |
|
| Outcome of acute promyelocytic leukemia (APL) in children and adolescents: an analysis in two consecutive trials of the European APL Group. |
|
| Outcome of patients aged 60-75 years with newly diagnosed secondary acute myeloid leukemia: A single-institution experience |
|
| Phenotypically-defined stages of leukemia arrest predict main driver mutations subgroups, and outcome in acute myeloid leukemia |
|
| Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. |
|
| Prognostic Implications of hyperleucocytic acute myeloid leukemia, results of the Tolosan experience between 1988 and 2005. |
|
| Real-World Outcomes of Patients with Refractory or Relapsed FLT3-ITD Acute Myeloid Leukemia: A Toulouse-Bordeaux DATAML Registry Study |
|
| Regulation of FLT3 and KIT protein expression in acute myeloid leukemia. |
|
| The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience |
|
| Risk of Hematologic Malignancies After Breast Cancer in France : A Population-Based Cohort Study. |
|
| Risque d'hémopathies malignes après cancer du sein : Études à partir des données du SNDS |
|
| Tyrosine kinases characterization and pharmacological targeting in acute myeloid leukemia : from signalization to epigenetic process. |
|
| Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study |
|
